Online inquiry

IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8647MR)

This product GTTS-WQ8647MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets AXL gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001278599.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 558
UniProt ID M0R0W6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8647MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8812MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ4462MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ4990MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ14576MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ5670MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ13251MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ8422MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ8614MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuM195
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW